Remdesivir, COVID-19, severe renal impairment, end stage renal disease, therapeutics

• Deniz AKYOL,
• Sinan MERMER,
• Hüsnü PULLUKÇU,
• Oğuz Reşat SİPAHİ,
• Dündar SABAH,
• Meltem IŞIKGÖZ TAŞBAKAN

Affiliations

Deniz AKYOL

ORCiD

Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey

Sinan MERMER

ORCiD

Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey

Hüsnü PULLUKÇU

ORCiD

Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey

Oğuz Reşat SİPAHİ

ORCiD

Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey

Dündar SABAH

ORCiD

Ege University Faculty of Medicine, Department of Orthopedics and Traumatology, İzmir, Turkey

Meltem IŞIKGÖZ TAŞBAKAN

ORCiD

Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey